As compliance pressure grows, enterprises are shifting away from fragmented safety processes toward centralized digital ...

Dec 6 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Vertex Pharmaceuticals' monopoly grants it significant pricing power, making it an inflation-resistant company. Mastercard's business is well-adapted to navigate inflationary periods; it also has a ...

Vertex Pharmaceuticals' monopoly grants it significant pricing power, making it an inflation-resistant company. Inflation can be a significant problem for investors in at least two ways. First, the ...

visjs / vis-timeline Public Notifications You must be signed in to change notification settings Fork 361 Star 2.3k ...

This strengthens Google’s position against rivals such as Microsoft and AWS as enterprises seek faster, more reliable ways to deploy and manage AI agents. Google Cloud has updated its Vertex AI Agent ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy. Vertex clocked 11% growth ...

I am writing as a private citizen, not in my capacity as a commissioner, to share some considerations regarding the current ballot measure. While the intent to promote accountability in public ...

With Doncic as their new franchise superstar, Bellchamber wrote that Rob Pelinka and the front office should focus on finding players at a similar age and point in their careers to maximize the ...

As global health threats continue to evolve rapidly, pharmaceutical leaders face mounting pressure to design development programs that can withstand volatility. From pandemics to geopolitical unrest ...